Proprietary Velvet Antler Stem Cell Extraction Technology Unlocks New Breakthroughs in Regenerative Medicine Applications

永立榮生醫推出首創鹿茸多肽保健食品與鹿茸幹細胞保養品

(TAIPEI, December 10, 2024) As Taiwan transitions into a aged society, rising health consciousness continues to drive demand for premium functional wellness products. U-NEURON (6973-TW), a pioneer in amniotic fluid stem cell regenerative medicine and aesthetic solutions, today officially launched its all-new velvet antler polypeptide nutraceuticals and velvet antler stem cell skincare series. Integrating cutting-edge amniotic fluid stem cell expertise with patented cellular technologies, U-NEURON is setting new standards in tissue repair and regeneration. This launch not only reinforces U-NEURON’s leading position in the biopharmaceutical sector, but its revolutionary extraction methodology also bridges natural bioactives with stem cell technology—marking a significant milestone in democratizing advanced biotechnology by integrating regenerative medicine into daily living.

Holding world-first patents for amniotic fluid stem cell isolation and culture, U-NEURON stands as the sole biotech enterprise globally to own comprehensive patent protection for amniotic fluid stem cell culture technologies, while becoming the first worldwide to develop deer amniotic fluid stem cell exosome cosmeceutical ingredients. In novel drug development, the company is accelerating developmentof its severe dry eye candidateUB003 and clinical trials of its erectile dysfunction candidateUA002. Within beauty and personal care, U-NEURON has successfully developed exosome raw materials derived from deer amniotic fluid, velvet antler, and human amniotic fluid stem cells, securing 5 international INCI registrations—ranking first among Taiwan biotech firms in stem cell exosome INCI listings. The launch of the velvet antler series demonstrates U-NEURON’s strategic expansion into precious natural bio-materials, enabling broader consumer populations to benefit from regenerative breakthroughs. At the launch event, dental regenerative medicine expert Dr. Shang-Ming Wang was featured as the brand advocate for the velvet antler series. Drawing on his extensive clinical and academic background across dentistry, life sciences, and neuroscience, Dr. Wang highlighted the regenerative value of velvet antler: “Velvet antler is the only mammalian organ capable of complete regeneration, harboring immense stem cell and polypeptide bioactivity. Its growth rate is extraordinary—reaching up to 1 inch per day—and it possesses the unique capacity to shed and fully regenerate annually.”

Dr. Wang emphasized U-NEURON’s strict adherence to animal welfare and environmental sustainability. Partnering with certified veterinarians and ethical deer farms, U-NEURON develops nutraceuticals and cosmeceuticals under stringent pharmaceutical-grade R&D standards. All velvet antler raw materials are sourced from certified farms using humane, non-harmful extraction processes that safeguard animal health and natural living conditions. Furthermore, U-NEURON actively adopts vegan formulation standards to support plant-based lifestyles and bring biotech innovations to diverse consumer demographics. Dr. Hsiao-Min Huang, President& CTO, and widely recognized pioneer of amniotic fluid stem cell research in Taiwan, detailed U-NEURON’s proprietary extraction technology. By selectively harvesting only the tips of velvet antlers—the most active growth zones enriched with high concentrations of amino acids, polypeptides, growth factors, cytokines, carbohydrates, and trace elements—U-NEURON utilizes proprietary AI extraction processes to isolate high-purity Activin-A. This breakthrough preserves core biological activity, optimizes absorption efficiency, and enhances stability to deliver superior cellular reactivation and restorative benefits in humans.

Yonglirong uses exclusive velvet antler extraction technology to launch new velvet antler peptide health food and velvet antler stem cell exosome care products, aiming to strengthen health from the root and emphasize two-way care, both internal and external. “Designed to enhance health from within and promote dual internal-external care, U-NEURON introduced two key product offerings:ACT-A Black Deer Supergene Capsules: Formulated specifically for male vitality, this wellness supplement combines the ACT-A velvet antler polypeptide revitalizing factor with organic maca, cistanche, turmeric extract, and L-arginine to boost core stamina, physical energy, and endurance.Encapsulated in vegan-friendly shells, the product adheres strictly to food cGMP standards to ensure scalable, standardized production. uses exosome technology to focus on skin cell repair and regeneration, providing users with skin care solutions for scalp hair, skin aging and skin tone brightening.

ExoBeauty All-in-One Miracle Exosome Series: Leveraging exosome delivery technology, this advanced skincare line focuses on cellular repair and tissue regeneration, offering tailored solutions for scalp revitalizing, hair rejuvenation, anti-aging, and skin brightening. As global demand for regenerative medicine solutions accelerates, U-NEURON leverages its proprietary technology platforms to convert high-end cell technologies into accessible commercial products. Chairman Dr. Frank Chien stated: “We are actively partnering with top-tier distributors and commercial channels while preparing to expand the market footprint of our velvet antler series from Taiwan into overseas international markets.” Looking ahead, U-NEURON will continue advancing its core stem cell R&D, international regulatory compliance, patent portfolios, and clinical trial pipelines to expand the commercial footprint of its regenerative platforms worldwide.

Disclaimer: This document contains forward-looking statements regarding future operations, clinical progression, and business outlooks of U-NEURON. Actual results may differ materially due to external variables including market competition, regulatory shifts, foreign exchange rates, and broader economic conditions. U-NEURON assumes no obligation to update these statements to reflect future events or circumstances.

This document and related information released simultaneously contain forward-looking statements. Except for facts that have already occurred, all descriptions of Yongliron’s (hereinafter referred to as the Company’s) future business operations, possible events and prospects (including but not limited to forecasts, targets, estimates and operating plans) are predictive statements. Forecast statements will be affected by different factors and uncertainties, resulting in considerable differences from actual conditions. These factors include but are not limited to price fluctuations, actual demand, exchange rate changes, market share, market competition, changes in legal, financial and regulatory frameworks, international economic and financial market conditions, political risks, cost estimates, etc., and other risks and variables beyond the control of the Company. These forward-looking statements are based on predictions and assessments of current conditions, and the Company is not responsible for updating them in the future.